Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hilton Foods sees 2025 in line as profits, dividend soar

(Sharecast News) - Hilton Foods said it was on track to deliver 2025 earnings in line with guidance after a sharp jump in profits last year, driven by its core retail meat business and despite the uncertain macroeconomic backdrop caused by US tariffs.

The company posted a 25% rise in pre-tax earnings to £61m in the year to December and hiked its dividend 7.8% to 34.5p. On an adjusted basis profits rose 15.3% to £76.1m.

"While the macro backdrop remains uncertain we are confident that we can deliver further earnings growth for the full year, in line with market expectations," the company said on Tuesday.

Analysts are forecasting adjusted pre-tax profits of £76.8m - £83.3m for the company, which supplies meat to retailers and hospitality businesses.

"Beyond the near term, we are well placed for continued success with a strong medium-term growth pipeline and recently secured opportunities in new geographies, underpinning our expansion strategy and long-term vision."

Hilton plans to launch in Saudi Arabia in the second half of next year and introducing its Hilton Foods Canada brand in early 2027.

UK and Europe core retail meat volumes outpaced the market, but there were "ongoing market challenges" at its vegetarian and vegan business, which reduced to a single production site last year as the market for meat-free options struggled amid a drop in consumer demand, "creating structural headwinds".

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.